P-50 Hybrid Boronic Acids as Potential Anti-cancer Agents in Glioblastoma Brain Cancer
Denise Smith & Desmond Murray.
AU Office of Research & Creative Scholarship.
Abstract
Glioblastoma (GBM) is arguably one of the most devastating types of brain cancer. Many therapeutic methods, including gene therapy, immunotherapy, and systemic chemotherapy, have shown some promise. However, many obstacles hinder the effectiveness of these methods. Hybrid boronic acids show some promise as potential antiglioblastoma agents because they have multiple pharmacophores, allowing for a wide range of therapeutic action. The purpose of this study is to investigate the synthesis and biological activity of hybrid boronic acids as potential antiglioblastoma agents. Various hybrid boronic acids were synthesized and tested on U87 MG gliobastoma cells. Cell viability was calculated with some compounds showing a decrease in cell growth.
P-50 Hybrid Boronic Acids as Potential Anti-cancer Agents in Glioblastoma Brain Cancer
Glioblastoma (GBM) is arguably one of the most devastating types of brain cancer. Many therapeutic methods, including gene therapy, immunotherapy, and systemic chemotherapy, have shown some promise. However, many obstacles hinder the effectiveness of these methods. Hybrid boronic acids show some promise as potential antiglioblastoma agents because they have multiple pharmacophores, allowing for a wide range of therapeutic action. The purpose of this study is to investigate the synthesis and biological activity of hybrid boronic acids as potential antiglioblastoma agents. Various hybrid boronic acids were synthesized and tested on U87 MG gliobastoma cells. Cell viability was calculated with some compounds showing a decrease in cell growth.